JP2008523083A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008523083A5 JP2008523083A5 JP2007545628A JP2007545628A JP2008523083A5 JP 2008523083 A5 JP2008523083 A5 JP 2008523083A5 JP 2007545628 A JP2007545628 A JP 2007545628A JP 2007545628 A JP2007545628 A JP 2007545628A JP 2008523083 A5 JP2008523083 A5 JP 2008523083A5
- Authority
- JP
- Japan
- Prior art keywords
- antagonist
- target
- multispecific
- targets
- inflammatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000005557 antagonist Substances 0.000 claims 27
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 230000000295 complement effect Effects 0.000 claims 6
- 239000012636 effector Substances 0.000 claims 6
- 230000000770 proinflammatory effect Effects 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 108020003175 receptors Proteins 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims 3
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- 208000034038 Pathologic Neovascularization Diseases 0.000 claims 3
- 239000003114 blood coagulation factor Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 102000034356 gene-regulatory proteins Human genes 0.000 claims 3
- 108091006104 gene-regulatory proteins Proteins 0.000 claims 3
- 230000002757 inflammatory effect Effects 0.000 claims 3
- 210000005007 innate immune system Anatomy 0.000 claims 3
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 2
- 101150013553 CD40 gene Proteins 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 2
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 claims 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 2
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 2
- 210000005006 adaptive immune system Anatomy 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 230000008938 immune dysregulation Effects 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 210000002540 macrophage Anatomy 0.000 claims 2
- 210000004180 plasmocyte Anatomy 0.000 claims 2
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 102000019034 Chemokines Human genes 0.000 claims 1
- 108010012236 Chemokines Proteins 0.000 claims 1
- 208000007465 Giant cell arteritis Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010018691 Granuloma Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 230000000392 somatic effect Effects 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 206010043207 temporal arteritis Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63407604P | 2004-12-08 | 2004-12-08 | |
| PCT/US2005/044446 WO2006063150A2 (en) | 2004-12-08 | 2005-12-08 | Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012248395A Division JP2013079240A (ja) | 2004-12-08 | 2012-11-12 | 炎症性疾患および免疫調節不全疾患、感染性疾患、病的血管新生およびがんの免疫療法および検出のための方法および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008523083A JP2008523083A (ja) | 2008-07-03 |
| JP2008523083A5 true JP2008523083A5 (enExample) | 2009-02-12 |
Family
ID=36578580
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007545628A Pending JP2008523083A (ja) | 2004-12-08 | 2005-12-08 | 炎症性疾患および免疫調節不全疾患、感染性疾患、病的血管新生およびがんの免疫療法および検出のための方法および組成物 |
| JP2012248395A Pending JP2013079240A (ja) | 2004-12-08 | 2012-11-12 | 炎症性疾患および免疫調節不全疾患、感染性疾患、病的血管新生およびがんの免疫療法および検出のための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012248395A Pending JP2013079240A (ja) | 2004-12-08 | 2012-11-12 | 炎症性疾患および免疫調節不全疾患、感染性疾患、病的血管新生およびがんの免疫療法および検出のための方法および組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (7) | US8420783B2 (enExample) |
| EP (1) | EP1819731A4 (enExample) |
| JP (2) | JP2008523083A (enExample) |
| AU (1) | AU2005313971B2 (enExample) |
| CA (1) | CA2587143C (enExample) |
| WO (1) | WO2006063150A2 (enExample) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| EP1441766B1 (en) * | 2001-10-16 | 2011-09-14 | MacroGenics West, Inc. | Antibodies that bind to cancer-associated antigen cd46 and methods of use thereof |
| JP2008523083A (ja) * | 2004-12-08 | 2008-07-03 | イムノメディクス， インコーポレイテッド | 炎症性疾患および免疫調節不全疾患、感染性疾患、病的血管新生およびがんの免疫療法および検出のための方法および組成物 |
| US20070099239A1 (en) * | 2005-06-24 | 2007-05-03 | Raymond Tabibiazar | Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease |
| EP2295080A3 (en) | 2005-07-25 | 2011-06-22 | Emergent Product Development Seattle, LLC | B-cell reduction using CD37-specific and CD20-specific binding molecules |
| CN105837690A (zh) | 2006-06-12 | 2016-08-10 | 新兴产品开发西雅图有限公司 | 具有效应功能的单链多价结合蛋白 |
| AU2007317333A1 (en) * | 2006-11-02 | 2008-05-15 | Seattle Genetics, Inc. | Methods of treating neoplastic, autoimmune and inflammatory diseases |
| KR101572700B1 (ko) * | 2007-06-07 | 2015-11-30 | 제넨테크, 인크. | 보체-관련 장애의 예방 및 치료를 위한 Ｃ３ｂ 항체 및 방법 |
| WO2009014633A1 (en) * | 2007-07-20 | 2009-01-29 | Trustees Of The University Of Pennsylvania | Method of treating acute respiratory distress syndrome |
| US8574577B2 (en) | 2008-01-03 | 2013-11-05 | The Scripps Research Institute | VEGF antibodies comprising modular recognition domains |
| US8557243B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | EFGR antibodies comprising modular recognition domains |
| KR101658247B1 (ko) | 2008-01-03 | 2016-09-22 | 더 스크립스 리서치 인스티튜트 | 모듈 인식 도메인을 통한 항체 표적화 |
| US8557242B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | ERBB2 antibodies comprising modular recognition domains |
| US8454960B2 (en) | 2008-01-03 | 2013-06-04 | The Scripps Research Institute | Multispecific antibody targeting and multivalency through modular recognition domains |
| US8940299B2 (en) * | 2008-02-28 | 2015-01-27 | Case Western Reserve University | Method of treating cancer |
| PT2132228E (pt) | 2008-04-11 | 2011-10-11 | Emergent Product Dev Seattle | Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional |
| CA2721713C (en) | 2008-05-05 | 2019-07-09 | Novimmune Sa | Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof |
| CN102171247A (zh) * | 2008-07-02 | 2011-08-31 | 特鲁比昂药品公司 | TNF-α拮抗剂多靶点结合蛋白 |
| CN102573906B (zh) * | 2009-02-06 | 2015-02-11 | 四川汇宇制药有限公司 | 抑免蛋白/亲环蛋白和emmprin免疫球蛋白受体超家族成员的双重抑制 |
| KR20120105405A (ko) * | 2009-06-23 | 2012-09-25 | 알렉시온 파마슈티칼스, 인코포레이티드 | 보체 단백질에 결합하는 이중특이적 항체 |
| US8623358B2 (en) | 2009-08-29 | 2014-01-07 | Abbvie Inc. | Therapeutic DLL4 binding proteins |
| JP2013518606A (ja) * | 2010-02-09 | 2013-05-23 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 新規使用 |
| EP2542582A4 (en) | 2010-03-02 | 2013-12-04 | Abbvie Inc | THERAPEUTIC PROTEINS LINKING TO DLL4 |
| WO2012009705A1 (en) | 2010-07-15 | 2012-01-19 | Zyngenia, Inc. | Ang-2 binding complexes and uses thereof |
| US8735546B2 (en) | 2010-08-03 | 2014-05-27 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| EP2714738B1 (en) | 2011-05-24 | 2018-10-10 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
| US20140255405A1 (en) * | 2011-05-27 | 2014-09-11 | Dutalys | Removal of Monomeric Targets |
| JP2013040160A (ja) * | 2011-07-01 | 2013-02-28 | Genentech Inc | 自己免疫疾患を治療するための抗ｃｄ８３アゴニスト抗体の使用 |
| WO2013088245A1 (en) * | 2011-12-12 | 2013-06-20 | Vascular Biogenics Ltd. | Treatment of inflammation |
| KR102023401B1 (ko) | 2012-05-10 | 2019-11-04 | 바이오아트라, 엘엘씨 | 다중-특이적 모노클로날 항체 |
| WO2014028862A1 (en) | 2012-08-17 | 2014-02-20 | Cornell University | Use of dna in circulating exosomes as a diagnostic marker for metastasic disease |
| WO2014066744A2 (en) | 2012-10-25 | 2014-05-01 | True North Therapeutics, Inc. | Anti-complement c1s antibodies and uses thereof |
| EP2912068B1 (en) * | 2012-10-26 | 2019-06-19 | Deutsches Rheuma-Forschungszentrum Berlin | Bi-specific antibodies for cell-lineage-specific tnf-alpha neutralisation |
| AU2013337775B2 (en) | 2012-11-01 | 2017-03-30 | Abbvie Inc. | Anti-VEGF/DLL4 dual variable domain immunoglobulins and uses thereof |
| PL2914291T3 (pl) | 2012-11-02 | 2022-10-03 | Bioverativ Usa Inc. | Przeciwciała anty-C1s dopełniacza i ich zastosowania |
| PT2951208T (pt) | 2013-02-01 | 2019-12-30 | Univ California | Anticorpos anti-cd83 e sua utilização |
| EP2774930A1 (en) | 2013-03-07 | 2014-09-10 | Aptenia S.R.L. | Metallocene compounds and labeled molecules comprising the same for in vivo imaging. |
| EP4202441A3 (en) | 2013-03-09 | 2023-07-26 | Immunis.AI, Inc. | Gene expression profile in macrophages for the diagnosis of cancer |
| WO2014164362A1 (en) | 2013-03-09 | 2014-10-09 | Harry Stylli | Methods of detecting prostate cancer |
| MX2015013163A (es) | 2013-03-15 | 2016-04-04 | Zyngenia Inc | Complejos multiespecificos multivalente y monovalentes y sus usos. |
| WO2014186622A2 (en) * | 2013-05-15 | 2014-11-20 | Annexon, Inc. | Methods of treatment for guillain-barre syndrome |
| WO2015006507A1 (en) | 2013-07-09 | 2015-01-15 | Annexon, Inc. | Methods of treatment for alzheimer's disease and huntington's disease |
| CA2924520C (en) | 2013-11-01 | 2023-09-26 | Ibc Pharmaceuticals, Inc. | Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune disease |
| US10844436B2 (en) | 2014-04-01 | 2020-11-24 | Cornell University | Use of double-stranded DNA in exosomes: a novel biomarker in cancer detection |
| EP3160504B1 (en) | 2014-06-24 | 2020-09-16 | Immunomedics, Inc. | Anti-histone therapy for vascular necrosis in severe glomerulonephritis |
| US10351621B2 (en) | 2014-06-24 | 2019-07-16 | Immunomedics, Inc. | Anti-histone therapy in acute kidney injury |
| WO2016025202A1 (en) * | 2014-08-14 | 2016-02-18 | The Regents Of The University Of Colorado | Antibody-sirna conjugates and uses therefor |
| US10626464B2 (en) | 2014-09-11 | 2020-04-21 | Cell Mdx, Llc | Methods of detecting prostate cancer |
| WO2016057702A2 (en) * | 2014-10-07 | 2016-04-14 | Cornell University | Methods for prognosing and preventing metastatic liver disease |
| ES3013108T3 (en) | 2014-11-05 | 2025-04-11 | Annexon Inc | Humanized anti-complement factor c1q antibodies and uses thereof |
| US9771385B2 (en) | 2014-11-26 | 2017-09-26 | Vascular Biogenics Ltd. | Oxidized lipids |
| ES2855299T3 (es) | 2014-11-26 | 2021-09-23 | Vascular Biogenics Ltd | Lípidos oxidados y tratamiento o prevención de la fibrosis |
| US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
| US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
| US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| CN107530376A (zh) | 2015-02-18 | 2018-01-02 | 恩立夫克治疗有限责任公司 | 用于癌症治疗的联合免疫疗法和细胞因子控制疗法 |
| US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| PL3280440T3 (pl) | 2015-04-06 | 2023-06-19 | Bioverativ Usa Inc. | Humanizowane przeciwciała anty-c1s i sposoby ich zastosowania |
| IL287500B2 (en) | 2015-04-21 | 2023-12-01 | Enlivex Therapeutics Rdo Ltd | Therapeutic pooled blood apoptotic cell preparations and uses thereof |
| WO2016172710A2 (en) | 2015-04-24 | 2016-10-27 | Cornell University | Methods and reagents for determination and treatment of organotropic metastasis |
| EP4190814A1 (en) | 2015-05-29 | 2023-06-07 | Amphivena Therapeutics, Inc. | Methods of using bispecific cd33 and cd3 binding proteins |
| TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白 |
| KR102784293B1 (ko) | 2015-09-21 | 2025-03-20 | 압테보 리서치 앤드 디벨롭먼트 엘엘씨 | Cd3 결합 폴리펩타이드 |
| CN115260310B (zh) | 2015-11-24 | 2025-02-25 | 安尼艾克松股份有限公司 | 抗补体因子c1q的fab片段及其应用 |
| CA3014885A1 (en) | 2016-02-18 | 2017-08-24 | Enlivex Therapeutics Ltd. | Combination immune therapy and cytokine control therapy for cancer treatment |
| EP4652926A3 (en) | 2016-10-12 | 2026-03-18 | Bioverativ USA Inc. | Anti-c1s antibodies and methods of use thereof |
| JP6944701B2 (ja) * | 2016-10-21 | 2021-10-06 | 国立大学法人山口大学 | ＣＤ１１ｂアンタゴニストを含む劇症型急性肺炎治療用組成物 |
| CN112513081A (zh) | 2018-06-14 | 2021-03-16 | 生物蛋白有限公司 | 多重特异性抗体构建体 |
| US20210324076A1 (en) * | 2018-10-12 | 2021-10-21 | Amphivena Therapeutics Inc | Cd33×cd3 binding proteins for treating inflammatory conditions and diseases |
| EP3902823A1 (en) | 2018-12-24 | 2021-11-03 | Sanofi | Multispecific binding proteins with mutant fab domains |
| MA54601A (fr) | 2018-12-24 | 2022-03-30 | Sanofi Sa | Nouvelles protéines de liaison multi-spécifiques à base de pseudofab |
| MA54945A (fr) | 2019-02-12 | 2021-12-22 | Regeneron Pharma | Compositions et procédés d'utilisation d'anticorps bispécifiques pour lier un complément et un antigène cible |
| US20220143153A1 (en) * | 2019-03-08 | 2022-05-12 | The Regents Of The University Of California | Compositions and methods for treating acne |
| US11045546B1 (en) | 2020-03-30 | 2021-06-29 | Cytodyn Inc. | Methods of treating coronavirus infection |
| WO2023114763A1 (en) | 2021-12-13 | 2023-06-22 | Annexon, Inc. | Anti-complement factor c1q antibodies with single binding arms and uses thereof |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5093117A (en) * | 1989-01-24 | 1992-03-03 | Baxter International Inc. | Compositions and method for the treatment or prophylaxis of sepsis or septic shock |
| US5256770A (en) * | 1990-04-09 | 1993-10-26 | Schering Ag | Oxidation resistant thrombomodulin analogs |
| GB8918232D0 (en) | 1989-08-10 | 1989-09-20 | Opal Stephen M | Pharmaceutical product for the treatment of septic shock |
| US5637481A (en) * | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| US6080407A (en) * | 1993-05-17 | 2000-06-27 | The Picower Institute For Medical Research | Diagnostic assays for MIF |
| ATE474597T1 (de) | 1993-05-17 | 2010-08-15 | Cytokine Pharmasciences Inc | Inhibition des migrations-inhibitions-faktors in der behandlung von krankheiten bei denen eine cytokin-vermittelte toxizität eine rolle spielt |
| US5830448A (en) * | 1994-06-16 | 1998-11-03 | Genentech, Inc. | Compositions and methods for the treatment of tumors |
| EP0771216B9 (en) | 1994-07-11 | 2003-01-02 | The Board Of Regents, The University Of Texas System | Methods and compositions for the specific coagulation of tumoral vasculature |
| US6290948B1 (en) * | 1996-05-14 | 2001-09-18 | Smithkline Beecham Corporation | Method of treating sepsis and ARDS using chamohine beta-10 |
| US6306393B1 (en) * | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| EP1079862B1 (en) * | 1998-05-20 | 2010-07-07 | Immunomedics, Inc. | Therapeutics using a bispecific anti-hla class ii invariant chain x anti-pathogen antibody |
| WO2000015259A1 (en) * | 1998-09-10 | 2000-03-23 | The University Of Virginia Patent Foundation | Antibodies to c3b(i) for delivery of diagnostic and therapeutic agents to cancer cells |
| US6572856B1 (en) * | 1998-09-10 | 2003-06-03 | The University Of Virginia Patent Foundation | Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies |
| CA2422204A1 (en) * | 2000-09-07 | 2002-03-14 | John R. Schreiber | Human antibodies against pseudomonas aeruginosa lps derived from transgenic mice |
| US20020192217A1 (en) * | 2001-03-07 | 2002-12-19 | Thierry Calandra | Methods for regulation of immune responses to conditions involving mediator-induced pathology |
| US20040242851A1 (en) * | 2001-06-26 | 2004-12-02 | Zhenping Zhu | Bispecific antibodies that bind to vegf receptors |
| WO2003007971A1 (en) * | 2001-07-17 | 2003-01-30 | University Of Virginia Patent Foundation | Improved heteropolymer complexes and methods for their use |
| RU2004127458A (ru) * | 2002-02-14 | 2005-10-27 | Иммуномедикс, Инк. (Us) | Анти-cd20 антитела, их гибридные белки и способы их использования |
| US7579000B2 (en) * | 2002-05-01 | 2009-08-25 | Bayer Schering Pharma Ag | Tissue factor targeted antibodies as anticoagulants |
| AU2003295330A1 (en) * | 2002-09-16 | 2004-05-04 | Elusys Therapeutics, Inc. | Bispecific molecule comprising an anti-cr1 antibody cross-linked to an antigen-binding antibody fragment |
| US7541440B2 (en) * | 2002-09-30 | 2009-06-02 | Immunomedics, Inc. | Chimeric, human and humanized anti-granulocyte antibodies and methods of use |
| EP1578397B1 (en) * | 2002-11-15 | 2012-12-26 | Genmab A/S | Human monoclonal antibodies against cd25 |
| ATE472556T1 (de) * | 2002-12-02 | 2010-07-15 | Amgen Fremont Inc | Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen |
| AU2003299641C1 (en) * | 2002-12-16 | 2016-06-02 | Cormorant Pharmaceuticals Ab | Human monoclonal antibodies against interleukin 8 (IL-8) |
| JP2006523090A (ja) | 2002-12-27 | 2006-10-12 | ドマンティス リミテッド | リガンドに、そしてリガンド受容体に特異的な二重特異性単一ドメイン抗体 |
| WO2004103294A2 (en) | 2003-05-15 | 2004-12-02 | Tanox, Inc. | Methods and compositions for the prevention and treatment of sepsis |
| US20050202010A1 (en) * | 2003-08-29 | 2005-09-15 | Giroir Brett P. | Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor |
| EP1668035A2 (en) * | 2003-09-11 | 2006-06-14 | Critical Therapeutics, Inc. | Monoclonal antibodies against hmgb1 |
| US8038996B2 (en) * | 2004-03-27 | 2011-10-18 | University Of Arizona | Composition and method for cancer treatment |
| JP2008523083A (ja) * | 2004-12-08 | 2008-07-03 | イムノメディクス， インコーポレイテッド | 炎症性疾患および免疫調節不全疾患、感染性疾患、病的血管新生およびがんの免疫療法および検出のための方法および組成物 |
| ES2829566T3 (es) * | 2005-03-03 | 2021-06-01 | Immunomedics Inc | Anticuerpos L243 humanizados |
| EP3243527B1 (en) * | 2009-02-13 | 2019-06-05 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
-
2005
- 2005-12-08 JP JP2007545628A patent/JP2008523083A/ja active Pending
- 2005-12-08 US US11/296,432 patent/US8420783B2/en not_active Expired - Fee Related
- 2005-12-08 EP EP05853383A patent/EP1819731A4/en not_active Ceased
- 2005-12-08 CA CA2587143A patent/CA2587143C/en not_active Expired - Fee Related
- 2005-12-08 AU AU2005313971A patent/AU2005313971B2/en not_active Ceased
- 2005-12-08 WO PCT/US2005/044446 patent/WO2006063150A2/en not_active Ceased
-
2007
- 2007-10-30 US US11/929,315 patent/US20080241141A1/en not_active Abandoned
- 2007-10-30 US US11/929,279 patent/US8420786B2/en not_active Expired - Fee Related
- 2007-10-30 US US11/929,221 patent/US20080108794A1/en not_active Abandoned
-
2012
- 2012-04-09 US US13/442,504 patent/US20120230953A1/en not_active Abandoned
- 2012-11-12 JP JP2012248395A patent/JP2013079240A/ja active Pending
- 2012-11-16 US US13/678,832 patent/US20130177498A1/en not_active Abandoned
- 2012-12-17 US US13/717,230 patent/US20130123473A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Briasoulis et al. | The role of inflammation and cell death in the pathogenesis, progression and treatment of heart failure | |
| Foss et al. | TRIM 21: a cytosolic Fc receptor with broad antibody isotype specificity | |
| JP2019520550A5 (enExample) | ||
| Steeland et al. | A new venue of TNF targeting | |
| Poignard et al. | gp120: biologic aspects of structural features | |
| WO2006063150A3 (en) | Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer | |
| JP2022109909A (ja) | 胸腺間質性リンパ球新生因子（ｔｓｌｐ）結合性抗体および抗体を使用する方法 | |
| Ding et al. | Emerging role of HMGB1 in lung diseases: friend or foe | |
| JP6883591B2 (ja) | 抗ヒトインターロイキン−１７ａモノクローナル抗体、その製造方法及び使用 | |
| JP6929786B2 (ja) | 強力な抗ｈｉｖ活性を有する二重特異性ｃｘｃｒ４−ｃｄ４ポリペプチド | |
| Hong et al. | Macrophage regulation of graft-vs-host disease | |
| JP2014076062A5 (enExample) | ||
| Szpakowska et al. | Human herpesvirus 8-encoded chemokine vCCL2/vMIP-II is an agonist of the atypical chemokine receptor ACKR3/CXCR7 | |
| JP2009521909A5 (enExample) | ||
| JP2005512507A5 (enExample) | ||
| HRP20191824T1 (hr) | Agonistička sredstva za vezivanje tnf receptora | |
| UA81743C2 (uk) | МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ | |
| WO2008106980A3 (en) | Recombinant antibodies for treatment of respiratory syncytial virus infections | |
| CN107207589A (zh) | 抗il‑25抗体及其使用方法 | |
| CN116715775A (zh) | 抗类胰蛋白酶抗体、其组合物及其用途 | |
| JP6535139B2 (ja) | Ｉｌ−１７ｃに対する抗体 | |
| Yu et al. | Ethyl pyruvate attenuated coxsackievirus B3-induced acute viral myocarditis by suppression of HMGB1/RAGE/NF-ΚB pathway | |
| JP2023532272A5 (enExample) | ||
| EA201290172A1 (ru) | Стабильные полипептиды, вариабельные домены антитела и антагонисты против tnfr1 | |
| CN117771365B (zh) | 一种抗狂犬病病毒组合单克隆抗体制剂 |